Abstract
Cancer is a global concern leading to millions of deaths every year. A declining trend in new drug discovery and development is becoming one of the major issues among the pharmaceutical, biotechnology industries and regulatory agencies. New drug development is proven to be a very lengthy and a costly process. Launch of a new drug takes 8-12 years and huge investments. Success rate in oncology therapeutics is also low due to toxicities at the pre-clinical and clinical trials level. Many oncological drugs get rejected at very promising stage showing adverse reactions on healthy cells. Thus, exploring new therapeutic benefits of the existing, shelved drugs for their anti-cancerous action could result in a therapeutic approach preventing the toxicities which occurs during clinical trials. Drug repurposing has the potential to overcome the challenges faced via conventional way of drug discovery and is becoming an area of interest for researchers and scientists. Although very few in vivo studies are conducted to prove the anti-cancerous activity of the drugs. Insufficient in vivo animal studies and lack of human clinical trials are the lacuna in the field of drug repurposing. This review focuses on the aspect of drug repurposing for cancer therapeutics. There are various studies which show that drugs approved for clinical indications other than cancer have shown promising anti-cancer activities. Some of the commonly used drugs like Benzodiazepines (Diazepam, Midzolam), Antidepressants (Imipramine, Clomipramine, and Citalopram), Antiepileptic (Valporic acid, Phenytoin), Anti diabetics (metformin) etc., have been reported to show potential activity against the cancerous cells.
Keywords: Drug Repurposing, non-cancerous drugs, secondary indication, anti cancerous activity, cancer therapeutics, drug development, new drug, costly process.
Current Pharmaceutical Design
Title:Anti-Cancer Potential of Some Commonly Used Drugs
Volume: 27 Issue: 45
Author(s): Pallavi Kumari and Shweta Dang*
Affiliation:
- Department of Biotechnology, Jaypee Institute of Information Technology, NOIDA, U.P.,India
Keywords: Drug Repurposing, non-cancerous drugs, secondary indication, anti cancerous activity, cancer therapeutics, drug development, new drug, costly process.
Abstract: Cancer is a global concern leading to millions of deaths every year. A declining trend in new drug discovery and development is becoming one of the major issues among the pharmaceutical, biotechnology industries and regulatory agencies. New drug development is proven to be a very lengthy and a costly process. Launch of a new drug takes 8-12 years and huge investments. Success rate in oncology therapeutics is also low due to toxicities at the pre-clinical and clinical trials level. Many oncological drugs get rejected at very promising stage showing adverse reactions on healthy cells. Thus, exploring new therapeutic benefits of the existing, shelved drugs for their anti-cancerous action could result in a therapeutic approach preventing the toxicities which occurs during clinical trials. Drug repurposing has the potential to overcome the challenges faced via conventional way of drug discovery and is becoming an area of interest for researchers and scientists. Although very few in vivo studies are conducted to prove the anti-cancerous activity of the drugs. Insufficient in vivo animal studies and lack of human clinical trials are the lacuna in the field of drug repurposing. This review focuses on the aspect of drug repurposing for cancer therapeutics. There are various studies which show that drugs approved for clinical indications other than cancer have shown promising anti-cancer activities. Some of the commonly used drugs like Benzodiazepines (Diazepam, Midzolam), Antidepressants (Imipramine, Clomipramine, and Citalopram), Antiepileptic (Valporic acid, Phenytoin), Anti diabetics (metformin) etc., have been reported to show potential activity against the cancerous cells.
Export Options
About this article
Cite this article as:
Kumari Pallavi and Dang Shweta *, Anti-Cancer Potential of Some Commonly Used Drugs, Current Pharmaceutical Design 2021; 27 (45) . https://dx.doi.org/10.2174/1381612827666210622104821
DOI https://dx.doi.org/10.2174/1381612827666210622104821 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Advances in Vaccine Adjuvants For Infectious Diseases
Current HIV Research KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions
Current Genomics Anti-Breast Cancer Agents from Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Vesicovaginal Fistula
Current Women`s Health Reviews Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets Synthesis and in vitro Evaluation of the Anticancer Potential of New Aminoalkanol Derivatives of Xanthone
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Current Cancer Drug Targets Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
Anti-Cancer Agents in Medicinal Chemistry The Discovery of HPV and its Clinical Implications
Current Cancer Therapy Reviews